Compare TransMedics Group Inc (TMDX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Ultra Short Bond ETF — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while Vanguard Ultra Short Bond ETF trades at $49.49 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is far larger — about 3.7× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 2,664,667). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| TMDX | VUSB | |
|---|---|---|
Market Cap | $2.74B | $10.20B |
Volume | 949,331 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $150.42 | $50.03 |
52-Week Low | $61.99 | $49.41 |
Typical Hold Time | 24 Days | 61 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
